Key terms
About SIBN
SI-BONE, Inc. is a medical device company, which engages in the provision of a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of musculoskeletal disorders of the sacropelvic anatomy. It offers a proprietary minimally invasive surgical implant system, called iFuse, used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. The company was founded by Mark A. Reiley and Jeffrey W. Dunn on March 18, 2008 and is headquartered in Santa Clara, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SIBN news
Today
7:20am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: SI-Bone (SIBN), Conmed (CNMD) and Chemed (CHE)
Apr 17
4:02am ET
Truist Financial Sticks to Their Buy Rating for SI-Bone (SIBN)
Apr 03
11:25am ET
SI-Bone’s Favorable Outlook and Buy Rating Amidst Stable Medical Coverage and Growth Prospects
Mar 28
6:40am ET
SI-Bone initiated with an Overweight at Piper Sandler
Mar 13
7:54am ET
Jefferies would be buyers of SI-Bone at current levels
Mar 13
6:38am ET
Buy Rating Affirmed for SI-Bone on Expansion and Market Growth Strategies
Feb 27
8:58am ET
SI-Bone price target lowered to $24 from $26 at Truist
Feb 27
8:36am ET
SI-Bone (SIBN) Gets a Buy from Cantor Fitzgerald
Feb 27
7:43am ET
Truist Financial Sticks to Its Buy Rating for SI-Bone (SIBN)
Feb 27
7:21am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: CSL (OtherCMXHF), Aurora Cannabis (ACB) and SI-Bone (SIBN)
Feb 27
5:49am ET
SI-Bone’s Strong Growth and Optimistic Profitability Outlook Justify Buy Rating
Feb 27
12:37am ET
SI-Bone’s Strong Outperformance and Promising Outlook Secure Buy Rating
Feb 26
4:32pm ET
SI-Bone sees FY24 revenue $162M-165M, consensus $159.06M
Feb 26
4:31pm ET
SI-Bone reports Q4 EPS (27c), consensus (28c)
Jan 30
8:35am ET
SI-Bone receives FDA 510k clearance for smaller diameter of iFuse Implant
No recent press releases are available for SIBN
SIBN Financials
Key terms
Ad Feedback
SIBN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SIBN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
